Explorer les evidences

2,1 aOROn multivariate analysis, female gender was associated with an adjusted odds ratio of 2.1 (95% CI 1.2–3.8) for vertical HIV transmission.

CamerounVIH/sidaobservé November 2007 to October 2010publié 2019Paediatrics and international child healthPubMeddocument de 7 observations

The frequency of substitutions at codons 39A, 43E, 122E, 312Q, 333E, 335C/D, 356K, 358K, 365I, 371V, 376S, and 399D in reverse transcriptase of subtype B ranged from <0.5% to 4%.

CamerounVIH/sidapublié 2011AIDS Research and Human RetrovirusesOpenAlexdocument de 24 observations

3,1 %HIV-1 seroprevalence was 3.1% among 1390 rural inhabitants in Cameroon.

CamerounVIH/sidapublié 2007AIDS (London, England)europe_pmcDOI 10.1097/qad.0b013e328045c4bd

7 %The prevalence of the 122E substitution in reverse transcriptase sequences was 7% among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublié 2011AIDS Research and Human RetrovirusesOpenAlexdocument de 24 observations

4 samplesAmong 55 HIV-1-positive samples from Cameroon, 4 (7.2%) had discordant subtypes between gag and env.

CamerounVIH/sidapublié 2000JAIDS Journal of Acquired Immune Deficiency SyndromesOpenAlexdocument de 6 observations

4 isolatesMajor mutations linked to resistance to non-NRTI agents were detected in all 4 group O isolates and in one subtype J virus.

CamerounVIH/sidapublié 2000Journal of Clinical MicrobiologyOpenAlexdocument de 19 observations

2,1 %Two point one percent of the 142 strains, all group O strains, had four mutations in the protease gene.

CamerounVIH/sidapublié 2000Journal of Clinical MicrobiologyOpenAlexdocument de 19 observations

12 %The prevalence of unsuppressed viral load among patients on first-line ART in rural Cameroon increased from 12.0% in the 6- to 12-month group to 31.3% in the >72-month group.

CamerounVIH/sidaobservé 2013-2014publié 2016Open Forum Infectious DiseasesOpenAlexdocument de 5 observationsDOI 10.1093/ofid/ofw233

16,4 %Among 128 patients routinely receiving highly active antiretroviral therapy in an HIV/AIDS outpatient clinic in Cameroon, 16.4% had drug resistance after a median of 10 months.

CamerounVIH/sidapublié 2006Emerging infectious diseasesOpenAlexdocument de 4 observationsDOI 10.3201/eid1206.050860

19,3 %Pretreatment HIV drug resistance (PDR) frequency was 19.3% in Cameroon.

CamerounVIH/sidapublié 2018Journal of Antimicrobial ChemotherapyOpenAlexdocument de 9 observationsDOI 10.1093/jac/dky443

47,3 %The prevalence of insulin resistance was 47.3% among HIV-infected adult Cameroonians aged 30 to 74 years at Yaoundé Central Hospital.

Camerouninsulin resistance · VIH/sidapublié 2017Lipids in health and diseaseeurope_pmcdocument de 7 observations

4 %The prevalence of the 60E substitution in protease sequences was 4% among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublié 2011AIDS Research and Human RetrovirusesOpenAlexdocument de 24 observations

Diastolic blood pressure was significantly increased with duration of highly active antiretroviral therapy (HAART) in HIV-infected Cameroonians.

CamerounVIH/sidapublié 2013Diabetes & metabolismeurope_pmcdocument de 12 observations

14 %The prevalence of the 358K substitution in reverse transcriptase sequences was 14% among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublié 2011AIDS Research and Human RetrovirusesOpenAlexdocument de 24 observations

18,6 %Prevalence was 18.6% on the final day of the health fair located at the parish trading center.

CamerounVIH/sidapublié 2012Journal of the International AIDS Societyeurope_pmcdocument de 39 observations

0,26 SMDHIV infection was associated with higher triglycerides with a standardized mean difference of 0.26.

Camerountriglycerides · VIH/sidapublié 2013International journal of epidemiologyeurope_pmcdocument de 10 observationsDOI 10.1093/ije/dyt198

2 %Clades A, F, CRF01_AE and CRF36_cpx each accounted for 2% of the studied HIV infections in Cameroonian blood donors.

CamerounVIH/sidapublié 2013Virology JournalOpenAlexdocument de 7 observationsDOI 10.1186/1743-422x-10-29

74 patientsAll 74 patients with antiretroviral drug resistance were resistant to nonnucleoside reverse-transcriptase inhibitors.

CamerounVIH/sidaobservé 2013-2014publié 2016Open Forum Infectious DiseasesOpenAlexdocument de 5 observationsDOI 10.1093/ofid/ofw233

10 %Five gag sequences (10%) were neither obviously recombinant nor easily classifiable into any of the known HIV-1M clades.

CamerounVIH/sidapublié 2013Virology JournalOpenAlexdocument de 7 observationsDOI 10.1186/1743-422x-10-29

5,6 %The V77I mutation was identified in 5.6% of the 142 HIV-1 isolates in the protease gene.

CamerounVIH/sidapublié 2000Journal of Clinical MicrobiologyOpenAlexdocument de 19 observations

10,4 %Pretreatment HIV drug resistance (PDR) prevalence among ART initiators with no prior exposure to antiretrovirals in Cameroon was 10.4% (95% CI 4.7%–21.5%).

CamerounVIH/sidaobservé 2015publié 2018The Journal of antimicrobial chemotherapyeurope_pmcdocument de 12 observationsDOI 10.1093/jac/dky221

73,6 %Among 458 patients who initiated antiretroviral therapy in rural district hospitals in Cameroon between 2006 and 2008, 337 (73.6%) were classified at WHO clinical stage 3.

CamerounVIH/sidaobservé 2006-2008publié 2010Tropical medicine & international health : TM & IHeurope_pmcdocument de 7 observations

-0,4 SMDHIV infection was associated with lower systolic blood pressure with a standardized mean difference of -0.40.

Camerounsystolic blood pressure · VIH/sidapublié 2013International journal of epidemiologyeurope_pmcdocument de 10 observationsDOI 10.1093/ije/dyt198

90,8 %Among 76 patients followed-up at endpoint, 90.8% had viremia <1000 copies/ml.

CamerounVIH/sidaobservé 2009-2011publié 2013PLoS ONEOpenAlexdocument de 8 observationsDOI 10.1371/journal.pone.0072680

8,6 %The rate of HCV coinfection among HIV-infected subjects in the study was 8.6%.

CamerounHCV coinfection · VIH/sidaobservé 2001publié 2007Emerging infectious diseasesOpenAlexdocument de 7 observationsDOI 10.3201/eid1303.061069